Indication
Recurrent Squamous Cell Carcinoma of the Oropharynx
2 clinical trials
3 products
5 drugs
Clinical trial
Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck.Status: Active (not recruiting), Estimated PCD: 2027-11-04
Drug
carboplatinDrug
AbraxaneDrug
fluorouracilDrug
hydroxyureaClinical trial
A Phase I Dose Escalation Study of the mTOR Inhibitor Everolimus (RAD001) and Erlotinib Concurrently With Radiation Therapy in the Re-Irradiation Setting for Head and Neck CancerStatus: Withdrawn, Estimated PCD: 2011-05-01
Drug
everolimusProduct
ErlotinibProduct
Microarray Analysis